Beacon Equity issues Trading Overview for AVI BioPharma Inc.
The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
(EMAILWIRE.COM, October 07, 2009 ) DALLAS, Texas - BeaconEquity.com announces an investment report featuring biopharmaceutical company AVI BioPharma Inc. (Nasdaq: AVII).
The investment report on AVI BioPharma Inc. (Nasdaq: AVII) should be of particular interest to other biopharmaceutical companies: Isis Pharmaceuticals (Nasdaq: ISIS), Enzo Biochem Inc. (NYSE: ENZ), Genta Inc. (OTCBB: GNTA) and Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY).
It is available at: http://www.beaconequity.com/i/AVII
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
AVI BioPharma Inc. (AVII) is an antisense drug development company focused upon providing a proprietary technology platform for the treatment of genetic disorders, infections and a range of other diseases. The Company's drug programs are in process of evaluation for the treatment of Duchenne muscular dystrophy and cardiovascular restenosis with its partner Global Therapeutics, a subsidiary of Cook Medical Company. Demonstrated drug efficacy against Ebola Zaire and Marburg Musoke viruses has attracted further investment in clinic trials funded by the U.S. Department of Defense.
In the report, the analyst notes:
“On October 5, 2009, the Company announced that it won additional funding and an expanded contract worth $11.5 million from the Defense Threat Reduction Agency’s (DTRA) Transformational Medical Technologies Initiative (TMTI) to further investigate the Company's drug candidate AVI-7012 for the treatment of the Junin virus. The recent award from TMTI brings the total contract value from the DoD to $45 million …
“The Company received clearance from the U.S. Food and Drug Administration (FDA) for clinical trials of its lead drug candidates to treat Ebola and Marburg viruses, representing the first TMTI-supported drug candidates to gain clearance targeting bioterrorism threats.”
To read the entire report visit: http://www.beaconequity.com/i/AVII
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
The investment report on AVI BioPharma Inc. (Nasdaq: AVII) should be of particular interest to other biopharmaceutical companies: Isis Pharmaceuticals (Nasdaq: ISIS), Enzo Biochem Inc. (NYSE: ENZ), Genta Inc. (OTCBB: GNTA) and Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY).
It is available at: http://www.beaconequity.com/i/AVII
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
AVI BioPharma Inc. (AVII) is an antisense drug development company focused upon providing a proprietary technology platform for the treatment of genetic disorders, infections and a range of other diseases. The Company's drug programs are in process of evaluation for the treatment of Duchenne muscular dystrophy and cardiovascular restenosis with its partner Global Therapeutics, a subsidiary of Cook Medical Company. Demonstrated drug efficacy against Ebola Zaire and Marburg Musoke viruses has attracted further investment in clinic trials funded by the U.S. Department of Defense.
In the report, the analyst notes:
“On October 5, 2009, the Company announced that it won additional funding and an expanded contract worth $11.5 million from the Defense Threat Reduction Agency’s (DTRA) Transformational Medical Technologies Initiative (TMTI) to further investigate the Company's drug candidate AVI-7012 for the treatment of the Junin virus. The recent award from TMTI brings the total contract value from the DoD to $45 million …
“The Company received clearance from the U.S. Food and Drug Administration (FDA) for clinical trials of its lead drug candidates to treat Ebola and Marburg viruses, representing the first TMTI-supported drug candidates to gain clearance targeting bioterrorism threats.”
To read the entire report visit: http://www.beaconequity.com/i/AVII
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
|
Weird Penny Stock Trick
We Found the #1 Way to Spot Penny Stocks That Explode Each Day! www.BeaconEquity.com FREE Penny Stock Alerts! Get Amazing Penny Stock ALERTS GetRichPicks.com How to buy Penny Stocks Learn the Skills, Make the Trades, Earn a Fortune! 100% Free to try. Chartpoppers.com Analyst Penny Stock Picks Visit StockSource.us for explosive stock picks, free stock research and trading tools www.StockSource.us Your text Ads here! Ads are only $575 per month. Ads are placed same day. Contac Us Emailwire.com/contact.php |